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Abstract
Background: Current HIV-1 antiretroviral therapy (ART) greatly reduces virus replication but does not significantly affect the
viral reservoir. Raltegravir, a recently introduced integrase inhibitor, could, at least theoretically, reduce residual viremia in
patients on ART and affect the viral reservoir size. The aim of this study was to assess whether switching therapy in
treatment-experienced patients that were virally suppressed to a raltegravir-containing regimen reduces the size of the viral
reservoir, and if such treatment leads to a change in levels of HIV 2-LTR circles in this patient group.
Methods: 14 ART experienced individuals with a suppressed viral load (,50 HIV-1 RNA copies/mL plasma) at baseline (for at
least 2 months) were switched to a raltegravir-containing regimen. Blood samples were taken at baseline and at $2
timepoints up to 4866 weeks. Levels of total HIV-1 DNA and 2-LTR circles in peripheral blood mononuclear cells (PBMCs)
were measured using real-time PCR assays.
Results: There was no significant change in HIV-1 total DNA levels over the study duration (p=0.808), median slope 0.24
(conservative nonparametric 95% CI: 211.78, 26.23). Low levels of 2-LTR circles were detected in 2 patients. One had 16
copies/10
6 PBMCs at baseline and the other had 34 copies/10
6 PBMCs at week 51.
Conclusions: The switch to a raltegravir containing regimen was not associated with a significant change in HIV-1 total DNA
levels in this cohort. There were no observed changes in the levels of HIV-1 2-LTR circles associated with raltegravir
treatment initiation.
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Introduction
The human immunodeficiency virus type 1 (HIV-1) viral
reservoir is established early in infection [1] and is the major
barrier to virus eradication and thus a cure for HIV-1 infec-
tion. [2,3,4]. Several mechanisms may contribute to the
maintenance of the viral reservoir including the homeostatic
dynamics within the CD4+ T cell pool, anatomical sanctuary
sites as well as low level ongoing replication and consequently
new rounds of virus infection. If ongoing replication despite
seemingly suppressive ART was a significant contributor for the
maintenance of the HIV-1 reservoir size, then intensification with
more potent agents or regimens may be able to further reduce
levels of HIV-1 DNA in peripheral blood of the treated
individuals. In support of ongoing replication, evidence of cross
infection has been demonstrated between resting and activated
CD4+ T cell compartments [5] and between GALT and
peripheral blood mononuclear cells (PBMCs) [6] in patients on
suppressive ART.
Raltegravir is an integrase inhibitor which has been shown to
significantly alter viral decay dynamics in treatment naive patients
[7], and which is also very effective in treatment experienced
patients [8]. In treatment experienced but virally suppressed
patients raltegravir could, at least theoretically, further inhibit the
HIV-1 life cycle by preventing integration of persisting linear non-
integrated HIV-1 DNA through the following mechanisms: direct
inhibition via its mechanism of action, increased pharmacological
penetrance into sanctuary sites compared to other antiretroviral
drugs [9], and/or by inhibiting linear non-integrated HIV-1 DNA
that had escaped only partially inhibitory upstream NRTI or
NNRTI therapy, for example from drug resistance mutations. We
hypothesized that raltegravir could affect the size of the HIV-1
reservoir by preventing its maintenance via the mechanisms listed
above. In the presence of ongoing replication, integrase inhibitors
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LTR circle increases have been detected after integrase inhibitor
treatment in cell culture [10], animal models [11], and in patients
[12].
At the time of study conception, there was no information on
the effects of raltegravir containing ART regimens on HIV-1
DNA levels. We hypothesized that in a treatment experienced
cohort, including patients on salvage therapy regimens with
potentially higher levels of residual viraemia, maintenance of the
viral reservoir through ongoing replication might be more
prevalent. Switching to a raltegravir containing regimen may
therefore further suppress ongoing replication in these patients
and have an impact on the size of the viral reservoir. We assessed
total HIV-1 DNA levels in PBMC as a measure of the viral
reservoir from 14 treatment experienced patients with suppressed
viral load (,50 HIV-1 RNA copies/mL plasma) at study entry
that were switched from their current ART to raltegravir
containing regimens. We also assessed levels of HIV-1 2-LTR
circles since changes in levels of episomal DNA after therapy
switch would be an indicator for the presence of ongoing
replication in this cohort.
Methods
Ethics statement
Written informed consent was obtained from all patients who
participated in this study. The study was approved by the human
research ethics committee, St Vincent’s Hospital, Sydney,
Australia (file number 08/SVH/58).
Participants
14 treatment experienced patients with suppressed viral load
(,50 HIV-1 RNA copies/mL plasma) at least two months prior to
study entry were switched from current ART to raltegravir
containing regimens. The decision to switch therapy was primarily
based on the treating physician’s attempt to achieve an optimised
treatment regime. Viral load was assessed using the standard
Roche COBAS Amplicor assay version 1.5 (Roche Diagnostics,
Pleasanton, USA). Blood samples were taken at baseline and at
approximately twelve-week intervals, with 2 or more subsequent
samples for each patient up to 4866 weeks.
DNA extraction
PBMCs were extracted from blood samples with Ficoll-Paque
gradient density centrifugation [13] and enumerated. DNA from
5–10 million PBMCs was extracted with the DNeasy Blood &
Tissue Kit (Qiagen Kit No 69504, Doncaster, Australia) according
to the manufacturer’s recommended protocol with some modifi-
cations: 1. The cell lysis step was extended to 16 hours. 2. The
DNA elution steps were extended to 1 hour each. 3. The AE
elution buffer was replaced with Tris-hydrochloride (Tris-HCL)
(10 mM, pH 8.0) (Invitrogen). The elution step was repeated to
obtain maximum yield. Extracted DNA was stored at 4uC.
Total HIV-1 DNA quantification with real-time PCR
HIV-1 DNA was quantified using a real-time PCR assay
targeting a highly conserved 155 base pair region of the gag gene as
previously described [14]. In brief, primers and probes used were:
HIV-gag sense primer SK145: 59- AGTGGGGGGACAT-
CAAGCAGCCATGCAAAT-39
HIV-gag antisense primer SKCC1B: 59- TACTAG-
TAGTTCCTGCTATGTCACTTCC-39
Fluorescent locked nucleic acid (LNA) probe SKLNA2–3:
59-6-FAM-AT[C]A[A]T[G]AGGAA[G]CT[G]C-TAMRA-39
Bases in brackets indicate locked nucleic acids (LNAs).
Patient samples and standard curve dilutions were run in
duplicate in 25 ml reactions with 12.5 ml of iQ Supermix (Bio-Rad
Laboratories, California, USA), 800 nM of SK145 and SKCC1B,
and 200 nM of SKLNA2–3. A maximum input of 500 ng DNA
(approximately 80,000 cells) input was used per reaction. DNA
from one HIV-1+ individual with known HIV-1 DNA copy
numbers was used as a reference control. The standard curve was
designed using linearised HIV-1 plasmid pNL4-3 in 7 serial 10-
fold dilutions from 10
7 to 10
1 copies. The limit of detection for the
assay was 10 copies. Cycling conditions for both assays were: 1
cycle 295uC for 3 minutes and 40 cycles 295uC for 15 seconds,
60uC for 1 minute on a Bio-Rad iQ-5 multicolour real-time PCR
machine (Bio-Rad Laboratories).
HIV-1 total DNA copy numbers were normalised with a
TaqMan beta-actin assay (Applied Biosystems, California, USA) to
determine copies per 500 ng genomic DNA input (under the
assumption that 8610
4 cells=500 ng of DNA), this was then
multiplied by 12.5 and displayed as copies per 10
6 PBMCs. All
samples from the same patient (baseline to 4866 weeks) were run
within the same PCR plate to enable comparison between
timepoints without the need to account for run-to-run variation.
All assays used non-template negative controls.
2-LTR circle quantification with real-time PCR
2-LTR circles were quantified using a real-time PCR assay
targeting a 297 base pair region of the 2-LTR junction. Primers
and probes used were:
Sense primer 2-LTR JF: 59-GCTAACTAGGGAACC-
CACTGCTTAAG-39
Antisense primer HIV R: 59-ACTGGTACTAGCTTGTAG-
CACCATCCA-39
LNA probe Mf374:
59-6-FAM-ACA[C]A[C]A[A]G[G][C]T-TAMRA-39
Patient samples were run in triplicate in 25 ml reactions with
12.5 ml of iQ Supermix, 280 nM of sense and antisense primers,
and 200 nM of Mf374. A maximum input of 500 ng DNA input
was used per reaction. Cycling conditions were as described in the
above assay with the second step increased to 45 cycles. Criteria
used to define a positive result were $2 of 3 wells with a threshold
cycle before or within 1 cycle of the 10
1 standard. An in house
HIV-1+ patient sample was used as a positive control. The
standard curve was designed using extracted plasmid DNA
containing the 2-LTR junction region in 7 serial 10-fold dilutions
from 10
7 to 10
1 copies. The limit of detection for the assay was 10
copies. 2-LTR circle copy numbers were normalised with a
TaqMan beta-actin assay as described above.
Statistical analysis
The HIV-1 total DNA results of each patient were graphed
against time. A linear trendline was plotted for each patient and
the slopes of the trendlines were calculated. The nonparametric
Wilcoxon Sign Rank test was used to evaluate if the median
slope significantly deviated from 0 (null hypothesis). The patients
were further sub-grouped by time of virological suppression
prior to baseline (,12 mths and $12 mths) and by reverse
transcriptase inhibitors in the treatment regimen. The Wilcoxon
Sign Rank test was then used to assess if the median slopes within
these subgroups deviated from 0. Again, a median trendline slope
of 0 (null hypothesis) would indicate no change in the HIV-1 DNA
levels over the study duration. All statistical analysis was
performed using GraphPad Prism version 5.0 c (GraphPad
Software, Inc).
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14 treatment experienced patients with suppressed viral load
(,50 HIV-1 RNA copies/mL plasma) at study entry were
switched to raltegravir containing regimens. The patients in the
study cohort were all male with a median age of 54.0 years (range
31.9–74.0). Table 1 shows the ART regimens of the study cohort
before and after the switch to raltegravir and the duration of
virologic suppression (,50 HIV-1 RNA copies/mL plasma) before
the switch (median: 21 mths, range: 2–60). All patients remained
virologically suppressed at all time points throughout the study.
HIV-1 Total DNA
HIV-1 total DNA was detectable in all patient samples. Figure 1
shows the levels of HIV-1 total DNA/10
6 PBMCs for each patient
(range: 71.3–28,564 copies/10
6 PBMCs). A linear trendline was
plotted for each patient, and the slope of each trendline was
obtained (Table 1). Figure 2 shows the slopes of the linear
trendlines for all patients (range: 285.8–229.2 copies/10
6 PBMCs
per week). A nonparametric one-sample Wilcoxon Sign Rank test
of the linear trendline slopes found no significant difference from 0
(p=0.808) and a median slope of 0.24 (conservative nonparamet-
ric 95% CI: 211.78, 26.23), indicating no change in the total
DNA levels over the study duration.
When the study cohort was subdivided into patients with ,12
months (n=4) and $12 months (n=10) of virologic suppression
prior to the switch to raltegravir (Figure 3A), analysis of the slopes
of trendlines in both groups demonstrated no significant difference
from 0 in either group (p=1.00 in ,12 months and p=0.770 for
$12 months). In a separate analysis, the study cohort was grouped
by inclusion (n=6) or lack of (n=8) reverse transcriptase inhibitors
(RTIs) in the treatment regimen after the switch (Figure 3B).
Neither group had a median trendline that was significantly
different from 0 (p=0.844 in both groups).
2-LTR circles
Two patients had detectable 2-LTR circles at one timepoint
each. Patient 018 had 16 copies/10
6 PBMCs at baseline and
Patient 014 had 34 copies/10
6 PBMCs at week 51 (Figure 4). No
2-LTR circles were detected in 12 of 14 patients. 2-LTR circles
were therefore not detected in 54 out of 56 total timepoints in the
study.
Discussion
This study assessed the impact of raltegravir on the levels of total
HIV-1 DNA and 2-LTR circles in 14 treatment experienced
patients with suppressed plasma viraemia before switching
therapy. Our results clearly demonstrate that a switch to a
raltegravir containing regimen in patients on stable ART was not
associated with a decay in HIV-1 total DNA over 4866 weeks. In
the setting of low-level residual viral replication, treatment
intensification or switching to a more potent regimen might be
expected to result in decay of the viral reservoir if ongoing
replication was essential to maintenance of the reservoir size.
Although the potency of raltegravir containing regimens remains
to be fully established, we did not observe any virological failure
during the first 48 weeks after switch of therapy, and also during
an extended observation of this cohort over 96 weeks (data not
shown). This includes those patients that were switched to a
simplified raltegravir/atazanavir regimen. Similar results were
reported in a recent study by Cordery et al. [15]. The stability of
HIV-1 DNA as demonstrated in our study therefore indicates that
inclusion of raltegravir to the treatment regimens did not
significantly alter the size of the viral reservoir.
These findings are in line with other recent studies [12,16,17]. It
is worth noting, that the clinical significance of changes in HIV-1
DNA levels in peripheral blood remains to be fully elucidated.
Yukl et al. [18] have recently demonstrated that the amount of
HIV-1 DNA in CD4+ T cells is on average 5–10 fold higher in the
Table 1. Study cohort characteristics and slope of HIV-1 Total DNA trendlines.
Patient ID Previous regimen Switch regimen
Virologic
suppression
(months) HIV-1 DNA level (copies/10
6 PBMCs)
Slope of
trendline*
Baseline Endpoint
001 FOS, TDF, FTC RAL, TDF, FTC 33 1587 4124 49.2
002 FOS, TDF, FTC RAL, TDF, FTC 7 7643 3154 285.8
011 LPV/r, ABC, 3TC RAL, ATV 57 2212 3867 26.2
012 LPV/r, ABC, 3TC RAL, TDF, FTC 2 4580 8105 229
013 EFV, FOS, LPV/r RAL, DRV/r 47 291 790 10.7
014 ATV/r, TDF, FTC RAL, ATV 24 1528 904 213.7
017 ATV/r, TDF, FTC RAL, ATV 11 579 116 26.89
018 DRV/r, TDF, FTC RAL, ATV, TDF, FTC 14 5824 4883 211.8
021 T20, DRV/r, TDF, FTC RAL, DRV/r, TDF, FTC 11 1281 1571 4.82
022 SQV, LPV/r RAL, DRV/r 60 381 643 7.01
023 AZT/3TC, DRV/r RAL, DRV/r 18 1456 1091 211.6
026 NVP, ABC, 3TC RAL, ATV 54 946 1462 10.1
027 SQV, ABC, 3TC, LPV/r RAL, DRV, 3TC 16 482 281 24.33
034 ABC, 3TC, SQV/r, ATV RAL, ATV 31 325 114 26.56
Note: All patients had HIV-1 RNA levels of ,50 copies per mL of plasma for the duration of the study. *: P-value not significant for all slopes. 3TC, lamivudine; ABC,
abacavir; ATV/r, ritonavir-boosted atazanavir; AZT, zidovudine; DRV/r, ritonavir-boosted darunavir; EFV, efavirenz; FOS, fosamprenavir; FTC, emtricitabine; LPV/r, ritonavir-
boosted lopinavir; NVP, nevirapine; RAL, raltegravir; SQV, saquinavir; T20, enfuvirtide; TDF, tenofovir.
doi:10.1371/journal.pone.0031990.t001
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size in the gut may exceed previous estimates of the total HIV
reservoir size by an order of magnitude. In another study, Chun et
al. [19] reported rebound of plasma viraemia following ART
interruption in an individual with undetectable HIV-1 DNA in
CD4+ T cells as well as GALT, and a profoundly low level of
replication competent virus, indicating that viral rebound may not
be indefinitely suppressed even in a patient with virtually
undetectable HIV DNA levels. Along with other studies
[12,16,17], our results show that the simple inclusion or addition
of an integrase inhibitor like raltegravir into an ART regimen is
unlikely to significantly reduce the size of the viral reservoir in
ART treated patients who already have suppressed plasma viral
loads. The clinical relevance of stability or changes in HIV-1 DNA
levels will require further exploration in future studies, and
additional markers of the viral reservoir size might be necessary to
better predict clinical outcome.
The persistence of ongoing rounds of viral suppression during
ART is currently a matter of debate. Findings that suggest ongoing
replication include the detection of HIV-1 RNA in lymphoid and
gut tissue as well as evidence of cross-infection between cellular
compartments in CD4+ T cells and GALT, despite undetectable
HIV-1 RNA in plasma [5,6,20,21,22]. However, recent pharma-
codynamic modeling indicates that current ART can fully inhibit
ongoing cycles of replication [23], and several other recent studies
also provide evidence against ongoing replication as a significant
mechanism through which the viral reservoir is maintained
[24,25,26,27]. We did not measure ultra low-level viraemia and
therefore cannot assess if raltegravir had an effect on residual
HIV-1 RNA levels independent of the total DNA results. However
this is unlikely since other studies have shown no change in low-
level viraemia with switching to raltegravir [28] or intensification
of treatment with raltegravir [27,29].
Low levels of 2-LTR circles, a possible surrogate marker of
ongoing replication during raltegravir treatment [12], were
detected in only 2 of 14 patients in our cohort. Increases in 2-
LTR circle levels have been shown to be associated with integrase
inhibitor activity in the presence of viral replication in vitro [30,31]
Figure 2. Slopes of HIV-1 total DNA trendlines for all patients.
The slopes of the linear trendlines for the study cohort are shown here.
The horizontal solid line indicates the median trendline slope. A
nonparametric one-sample Wilcoxon Sign Rank test of the slopes
demonstrated no significant difference from 0 (p=0.808), indicating no
change in the total DNA levels of the cohort over the study duration.
doi:10.1371/journal.pone.0031990.g002
Figure 1. Plot of HIV-1 total DNA results for individual patients. Plots of the 14 study patients: Each plot depicts an individual patient’s levels
total HIV-1 DNA levels in PBMCs (black ‘X’es) from baseline (week 0) to study endpoint. Solid lines are linear trendlines and may appear curved due to
the log scale of Y-axis. The linear trendline demonstrates if the level of HIV-1 total DNA increased or decreased in each patient after the switch to a
raltegravir-containing regimen.
doi:10.1371/journal.pone.0031990.g001
Figure 3. Slopes of HIV-1 total DNA trendlines grouped by A) duration of virologic suppression prior to switch, and B) RTIs in
switch regimen. Panel A) The study cohort was grouped into ,12 months (n=4) and $12 months (n=10) of virologic suppression prior to the
switch to a raltegravir-containing regimen. Analysis of the slopes of trendlines showed no significant difference from 0 in either group (p=1.00 in
,12 months and p=0.770 for $12 months), indicating no effect of length of suppression prior to switching on the attenuation of total HIV-1 DNA
levels. Panel B) The study cohort was grouped by the inclusion (n=6) or lack of (n=8) RTIs in the switch regimen. Analysis of the slopes of trendlines
showed no significant difference from 0 in either group (p=0.844 in both groups), indicating no measurable effect of the inclusion or lack of RTIs in
our study cohort.
doi:10.1371/journal.pone.0031990.g003
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circle levels after switching to raltegravir, together with the lack of
change in HIV-1 total DNA levels, most likely reflect only minimal
or no ongoing replication in this cohort. Again, our results are in
line with findings from Delaugerre et al. [16], who also did not
detect increases in 2-LTR circles 24 and 48 weeks after the switch
to a raltegravir-containing regimen in treatment experienced
patients. In another study, Buzon et al. [12] identified increases in
2-LTR circles at 2 and 4 weeks after treatment intensification with
raltegravir in virologically suppressed patients, mainly in those
who had been on a protease inhibitor containing regimen. Two
other studies in treatment naive patients [32,33] indicate that peak
changes in 2-LTR circles occur within the first 12 weeks after
treatment initiation with or without the inclusion of an integrase
inhibitor in the treatment regimen. One limitation of our study
was that the earliest follow-up measurement was more than 12
weeks after baseline for many patients, and any early increases in
2-LTR circles might therefore have been missed. In addition,
quantitative assays for measuring 2-LTR circles are also
technically demanding due to the high sequence variability of
the 2-LTR junction region [30], so the lack of detectable changes
in 2-LTR levels might be, at least in part, a result of these
limitations.
In summary, our results demonstrate that the switch to a
raltegravir containing regimen in a cohort of treatment experi-
enced, virologically suppressed patients was not associated with a
decay in HIV-1 total DNA over 4866 weeks, and indicates that
this change in treatment regimen did not have a significant impact
on the viral reservoir size or mechanisms of maintenance. The
inclusion, or as other groups have shown the addition of
raltegravir to an ART regimen is thus unlikely to contribute
significantly to reservoir clearance without other interventions.
Future studies exploring therapeutic approaches to eradication of
HIV-1 infection will likely need to attempt to specifically target
latently infected cells in addition to the complete reduction of all
ongoing replication. Finally, the clinical relevance of changes of
cell associated HIV-1 DNA levels in the setting of therapeutic
strategies that aim at reducing the HIV reservoir will also need to
be more clearly established.
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